CTLA4 and glioma: Indeed, G47Δ-mIL12, anti-CTLA4, and anti-PD-1 triple therapy showed surprising results, curing most mice in glioma models and outperforming G47Δ-mIL12, anti-CTLA4, and anti-PD-1 alone in prolonging survival [41].